Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091832 | 0.84 | KMT2A (0.44) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL2360748 | 0.80 | PLAU (0.61) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL266609 | 0.79 | ALDH1A1 (0.66) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL29727934 | 0.79 | ALDH1A1 (0.66) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL827359 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL172440 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL229608 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL15947574 | 0.76 | ALDH1A1 (0.61) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL9305169 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL436153 | 0.76 | ALDH1A1 (0.63) | KMT2APOLBALDH1A1HPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730309-B1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | IONIS PHARMACEUTICALS INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2700720-A2 | Compositions and methods for optimizing cleavage of RNA by RNASE H | Isis Pharmaceuticals, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | SMITH LARRY J (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2010120262-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MEDICAL CONDITIONS INVOLVING CELLULAR PROGRAMMING | SMITH HOLDINGS, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1730309-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | Isis Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005089268-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | KMT2A 2859/4885POLB 353/4885ALDH1A1 3259/4885 |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | CKMT1A; CKMT1B, ATF4, NFATC1 | KMT2A 912/4885POLB 162/4885ALDH1A1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.